Loading patent…
AssigneeBanyu Pharmaceutical Co., Ltd.
InventorsHirobumi Takahashi, Yuichi Sugimoto, Takashi Yoshizumi, Tetsuya Kato, Masanori Asai, Hiroshi Miyazoe
Estimating the term…
Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.
1-29. (canceled)
A compound of the formula I:
The compound of claim 29 wherein A4 is —N—, A1 is —C(R5)—, A2 is —C(R5)— and A3 is —C(R5)—.
The compound of claim 29 wherein A5 is —C(R6)—, A6 is —C(R6)— A7 is —C(R6)— and A8 is —C(R6)—.
The compound of claim 29 wherein A7 is —N—, A5 is —C(R5)—, A6 is —C(R6)—, and A8 is —C(R6)—.
The compound of claim 29 wherein R6 is selected from a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, an isopropyl group, a trifluoromethyl group, a methylcarbonyl group, a methoxymethyl group, a formyl group and a cyano group.
The compound of claim 29 wherein R1 and R1′ are selected from a hydrogen atom, a hydroxyl group, a methyl group, a methoxy group, a methylsulfonylamino group and a methylcarbonylamino group.
The compound of claim 29 wherein R1 and R1′ together form an oxo group or an ethylene-ketal group.
The compound of claim 29 wherein R2 and R2′ are both hydrogen atoms.
The compound of claim 29 wherein R2 and R2′ together form —CH2CH2—.
The compound of claim 29 wherein R3 and R3′ are selected from a hydrogen atom, a hydroxyl group, a fluorine atom, a methoxy group, a methyl group, a hydroxymethyl group, a fluoromethyl group, a methanesulfonylaminomethyl group, a methanesulfonylmethylaminomethyl group, a methoxycarbonylaminomethyl group and a dimethylsulfamoylaminomethyl group.
The compound of claim 29 wherein R4 is selected from a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a cyano group, a formyl group and a trifluoromethyl group.
The compound of claim 29 wherein R4 and R7 together form —CH2—O—, —CH(CH3)—O—, —C(CH3)2—O— or —N(CH3)—CH2—.
The compound of claim 29 wherein Z is —C(R7)—, and R7 is selected from a hydrogen atom, a fluorine atom and a methyl group.
The compound of claim 29 wherein X is —CH2—, —O— or —N(CH3)—.
The compound of claim 29 wherein n is 0.
The compound of claim 29 wherein n is 1 and Y is —CH2—.
A compound which is selected from the group consisting of:
A compound which is selected from the group consisting of:
A pharmaceutical composition which comprises an inert carrier and a compound of claim 20, or a pharmaceutically acceptable salt thereof.
A method for treating a disease or disorder selected from the group consisting of:
Dependencies are inferred from the claim text.